Overview

Genetics of QT Prolongation With Antiarrhythmics

Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
To assess the ability of common genetic variants in aggregate to predict drug-induced QT prolongation in patients being loaded with dofetilide or sotalol.
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Mayo Clinic
The Cleveland Clinic
University of Colorado, Denver
VA Office of Research and Development
Treatments:
Anti-Arrhythmia Agents
Dofetilide
Sotalol